Add time:08/29/2019         Source:sciencedirect.com

Protein kinase inhibitors (PKI) are a growing class of anticancer agents. They are prescribed with flat doses, and their oral administration is associated with interindividual variability in exposure. Patients can be over- or underexposed, due to numerous factors. We reviewed key pharmacokinetic concepts and mechanisms by which PKIs prescription could be altered. Challenging situations that could lead to increased toxicity or to therapeutic failure are described and recommendation for clinicians are proposed. Finally, the interest of therapeutic drug monitoring and indications for its use in daily practice is discussed.

We also recommend Trading Suppliers and Manufacturers of protein kinase inhibitor M (6-24) (cas 136058-51-0). Pls Click Website Link as below: cas 136058-51-0 suppliers